Trial Summary
What is the purpose of this trial?
This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether give durvalumab and tremelimumab in combination or sequential administration works better in treating participants with ovarian, primary peritoneal, or fallopian tube cancer.
Research Team
Amir A. Jazaeri
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for adults with recurrent or resistant ovarian, primary peritoneal, or fallopian tube cancer. Participants must be over 18 years old, have a good performance status (able to carry out daily activities), and have proper organ function. They should not be pregnant and must use effective birth control if of reproductive potential.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Durvalumab (Checkpoint Inhibitor)
- Tremelimumab (Checkpoint Inhibitor)
Durvalumab is already approved in Japan for the following indications:
- Not specified in provided sources
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor